<DOC>
	<DOCNO>NCT01429831</DOCNO>
	<brief_summary>The study aim evaluate effectiveness tolerability aripiprazole augmentation outpatient major depressive disorder inadequate response antidepressant Taiwan clinical practice .</brief_summary>
	<brief_title>Aripiprazole Augmentation Antidepressant Therapy</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Outpatients , either gender , 2065 year age Patients diagnose major depressive disorder define Diagnostic Statistical Manual Mental Disorders ( DSMIV ) , fulfill follow criterion : Having least one three inadequate response antidepressant HAMD17 score ≥ 14 Willing able comply study procedure sign write informed consent Females pregnant/lactating plan pregnant Presence personality disorder cluster B ( dramatic , emotional erratic disorder ) psychotic symptomatology current depressive episode base Investigators judgment History organic mental disorder within 1 year prior screen visit Acute risk suicide attempt within 3 month prior initiation study treatment ( HAM D17 score item 3 ≥ 3 ) Electroconvulsive therapy ( ECT ) current episode Past exposure aripiprazole treatment investigational product ( include drug invasive medical device ) within 4 week prior initiation study treatment History substance / alcohol abuse within 1 year prior screen visit Patient medical psychotic feature , include presence significant abnormal laboratory value , consider suitable study Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>